ClinicalTrials.Veeva

Menu

A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®

AstraZeneca logo

AstraZeneca

Status and phase

Completed
Phase 3

Conditions

Asthma

Treatments

Drug: Terbutaline Turbuhaler
Drug: Budesonide/Formoterol Turbuhaler
Drug: Budesonide Turbuhaler (Pulmicort)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00244608
D5890C00003
EudraCT no. 2004-004042-41

Details and patient eligibility

About

The purpose of this study is to determine if a flexible dose of Symbicort has a similar effect on the airways of patients with asthma as a higher fixed-dose of Symbicort with additional glucocorticosteroids added.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of asthma for at least 6 months
  • Prescribed daily use of glucocorticosteroids for at least 3 months prior to visit one

Exclusion criteria

  • Respiratory infection affecting asthma within 30 days prior to study
  • Intake of oral, rectal, or parenteral glucocorticosteroids within 30 days prior to study
  • Any significant disease or disorder that may jeopardize the safety of the patient

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

22

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems